OBJECTIVES: To determine the clinical outcome and prognostic factors for overall survival in children with recurrent and/or primary refractory Hodgkin disease (HD) after high-dose therapy and autologous hemopoietic stem cell transplantation (AHSCT). The survival outcome of this treatment was compared with conventional salvage therapy without stem cell transplantation. METHODS: Clinical records of 51 patients with relapsed or refractory HD who underwent AHSCT were reviewed. The source of the stem cells was bone marrow (n = 22) or peripheral blood (n = 29). At the time of high-dose therapy, 39 patients were in complete remission and 1 was in partial remission, while the remaining 11 had refractory disease. The records of 78 patients from the HD 1 trial who underwent conventional salvage treatment but without AHSCT for relapsed or refractory HD were also reviewed. All patients received HDT without radiation for conditioning. RESULTS: Overall survival from diagnosis of patients treated with AHSCT did not differ significantly from that of those treated with conventional salvage therapy (hazard ratio = 1.5; 95% confidence interval = 0.9-8.2; P = 0.4). There were also no statistically significant differences in survival data between the two approaches for patients whose duration of first remission was less than or greater than 1 year (P = 0.5; stratified log-rank). Of the 11 patients who received AHSCT for refractory disease, 9 remain alive and well with followups ranging from 2 to 18 years. No deaths due to treatment-related complications were seen in the AHSCT group. CONCLUSIONS: Stem cell transplantation does not offer any significant survival advantage over conventional salvage therapy in children with relapsed HD, although it may be of benefit for patients with primary refractory disease.
OBJECTIVES: To determine the clinical outcome and prognostic factors for overall survival in children with recurrent and/or primary refractory Hodgkin disease (HD) after high-dose therapy and autologous hemopoietic stem cell transplantation (AHSCT). The survival outcome of this treatment was compared with conventional salvage therapy without stem cell transplantation. METHODS: Clinical records of 51 patients with relapsed or refractory HD who underwent AHSCT were reviewed. The source of the stem cells was bone marrow (n = 22) or peripheral blood (n = 29). At the time of high-dose therapy, 39 patients were in complete remission and 1 was in partial remission, while the remaining 11 had refractory disease. The records of 78 patients from the HD 1 trial who underwent conventional salvage treatment but without AHSCT for relapsed or refractory HD were also reviewed. All patients received HDT without radiation for conditioning. RESULTS: Overall survival from diagnosis of patients treated with AHSCT did not differ significantly from that of those treated with conventional salvage therapy (hazard ratio = 1.5; 95% confidence interval = 0.9-8.2; P = 0.4). There were also no statistically significant differences in survival data between the two approaches for patients whose duration of first remission was less than or greater than 1 year (P = 0.5; stratified log-rank). Of the 11 patients who received AHSCT for refractory disease, 9 remain alive and well with followups ranging from 2 to 18 years. No deaths due to treatment-related complications were seen in the AHSCT group. CONCLUSIONS: Stem cell transplantation does not offer any significant survival advantage over conventional salvage therapy in children with relapsed HD, although it may be of benefit for patients with primary refractory disease.
Authors: Monika L Metzger; Melissa M Hudson; Matthew J Krasin; Jianrong Wu; Sue C Kaste; Larry E Kun; John T Sandlund; Scott C Howard Journal: Cancer Date: 2010-09-15 Impact factor: 6.860
Authors: Christopher L Tinkle; Noelle L Williams; Huiyun Wu; Jianrong Wu; Sue C Kaste; Barry L Shulkin; Aimee C Talleur; Jamie E Flerlage; Melissa M Hudson; Monika L Metzger; Matthew J Krasin Journal: Radiother Oncol Date: 2019-02-05 Impact factor: 6.280
Authors: Brian D Friend; Ibrahim N Muhsen; Shreeya Patel; LaQuisa C Hill; Premal Lulla; Carlos A Ramos; S Ravi Pingali; Rammurti T Kamble; Tami D John; Baheyeldin Salem; Saleh Bhar; Erin E Doherty; John Craddock; Ghadir Sasa; Mengfen Wu; Tao Wang; Caridad Martinez; Robert A Krance; Helen E Heslop; George Carrum Journal: Bone Marrow Transplant Date: 2022-02-01 Impact factor: 5.483
Authors: P Satwani; K W Ahn; J Carreras; H Abdel-Azim; M S Cairo; A Cashen; A I Chen; J B Cohen; L J Costa; C Dandoy; T S Fenske; C O Freytes; S Ganguly; R P Gale; N Ghosh; M S Hertzberg; R J Hayashi; R T Kamble; A S Kanate; A Keating; M A Kharfan-Dabaja; H M Lazarus; D I Marks; T Nishihori; R F Olsson; T D Prestidge; J M Rolon; B N Savani; J M Vose; W A Wood; D J Inwards; V Bachanova; S M Smith; D G Maloney; A Sureda; M Hamadani Journal: Bone Marrow Transplant Date: 2015-08-03 Impact factor: 5.483